How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Neuraminidase Inhibitor Market
- By Drug Type: Oseltamivir, Zanamivir, Peramivir, Laninamivir
- By Formulation: Oral Capsules, Oral Suspension, Inhalation Powder, Intravenous Injection
- By Indication: Influenza A, Influenza B, Prophylaxis of Influenza
- By End User: Hospitals, Clinics, Home Care Settings, Pharmacies
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Oseltamivir leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Neuraminidase Inhibitor Market report
A complete, evidence-based study - 12 chapters and 118 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Drug Type 4
Formulation 4
Indication 3
End User 4
Distribution Channel 3
Companies profiled
Roche Holding AG
GlaxoSmithKline plc
Hetero Drugs Limited
Cipla Limited
Sun Pharmaceutical Industries Ltd
Mylan N.V.
Zhejiang Hisun Pharmaceutical Co. Ltd.
Aurobindo Pharma Limited
Dr. Reddy's Laboratories Ltd.
Lupin Limited
Sandoz (a Novartis division)
Biocon Limited
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Hetero Drugs Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cipla Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sun Pharmaceutical Industries Ltd
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mylan N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Zhejiang Hisun Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Aurobindo Pharma Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dr. Reddy's Laboratories Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Lupin Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Sandoz (a Novartis division)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Biocon Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,092M by 2033 · 11.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Oseltamivir61.9
- Zanamivir8.3
- Peramivir14.1
- Laninamivir15.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,130M → $2,617M · 11.1%
Europe$787.8M → $1,776M · 10.7%
Asia Pacific$719.3M → $1,596M · 10.5%
Latin America$445.3M → $940.6M · 9.8%
Middle East and Africa$342.5M → $829.4M · 11.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.312026
11.302027
11.332028
11.342029
11.352030
11.362031
11.382032
11.382033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Holding AG14.4
- GlaxoSmithKline plc24.4
- Hetero Drugs Limited8.1
- Cipla Limited10.5
- Sun Pharmaceutical Industries Ltd5.6
- Mylan N.V.9.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type12.4%
Formulation14.5%
Indication23.8%
End User25.3%
Distribution Channel24.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.7
- Europe22.9
- Asia Pacific20.6
- Latin America12.1
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Holding AG | 79 | 81 | 97 | 98 | 98 | 97 | 92 |
| GlaxoSmithKline plc | 84 | 77 | 78 | 88 | 91 | 93 | 85 |
| Hetero Drugs Limited | 63 | 88 | 64 | 77 | 82 | 81 | 76 |
| Cipla Limited | 80 | 75 | 57 | 76 | 70 | 68 | 71 |
| Sun Pharmaceutical Industries Ltd | 53 | 77 | 71 | 74 | 72 | 67 | 69 |
| Mylan N.V. | 67 | 62 | 53 | 52 | 57 | 58 | 58 |
| Zhejiang Hisun Pharmaceutical Co. Ltd. | 43 | 62 | 58 | 49 | 44 | 51 | 51 |
| Aurobindo Pharma Limited | 56 | 57 | 53 | 45 | 46 | 48 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Holding AG
- GlaxoSmithKline plc
- Hetero Drugs Limited
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Holding AG | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| GlaxoSmithKline plc | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Hetero Drugs Limited | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Cipla Limited | ◐ | ◐ | − | ✓ | ✓ | ✓ |
| Sun Pharmaceutical Industries Ltd | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Mylan N.V. | − | − | ◐ | − | ◐ | ◐ |
| Zhejiang Hisun Pharmaceutical Co. Ltd. | − | ◐ | − | − | − | − |
| Aurobindo Pharma Limited | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Holding AG92
2GlaxoSmithKline plc85
3Hetero Drugs Limited76
4Cipla Limited71
5Sun Pharmaceutical Industries Ltd69
6Mylan N.V.58
7Zhejiang Hisun Pharmaceutical Co. Ltd.51
8Aurobindo Pharma Limited51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Roche Holding AGGlaxoSmithKline plc
Challenger3
Strong scale, closing on the leaders.
Hetero Drugs LimitedCipla LimitedSun Pharmaceutical Industries Ltd
Contender1
Focused players with pockets of strength.
Mylan N.V.
Niche2
Specialists in a single segment or region.
Zhejiang Hisun Pharmaceutical Co. Ltd.Aurobindo Pharma Limited
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across Neuraminidase Inhibitor Market — a $502M beachhead inside a $8.43B market.
Beachhead (SOM)$502Mobtainable near-term
Serviceable (SAM)$3.33Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Oseltamivir
Best fit — highest urgency & budget in Drug Type.
Economic buyer77 fit
Zanamivir
Strong fit — clear ROI and a fast path to value.
End user66 fit
Peramivir
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Formulation & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel31%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Neuraminidase Inhibitor Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation15%
Closed-won6%
$12.1KCAC
$55KLTV
4.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Neuraminidase Inhibitor Market is a resilient opportunity — $7.11B by 2033, compounding at 4.7%.
TAM · 2025$4.93Btoday
TAM · 2033$7.11Bforecast
CAGR4.7%2027–2033
Cumulative$53.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.11BTotal addressable market
SAM$2.74BServiceable available market
SOM$592MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.11BLarge & growingTAM by 2033 at 4.7% CAGR
$2.74BServiceable nowreachable with today’s model
$592MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.55BBear3.1% CAGR
$7.11BBase4.7% CAGR
$9.10BBull6.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Formulation optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Neuraminidase Inhibitor Market — a $3.88B market by 2033. Plan: grow share from 7.5% to 11.6%.
Market size · 2033$3.88Btotal addressable
Market CAGR5.7%2027–2033
Target share11.6%from 7.5% today
Revenue ambition$451Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.5% | 11.6% | On track |
| Revenue | $312M | $451M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 29.5% | 39.3% | At risk |
| Customer retention | 91.6% | 94.6% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Formulation capability
A defensible second engine — invest in Formulation to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Formulation
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $61M capacity & capability investment
- Greenlight bolt-on M&A in Formulation
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Neuraminidase Inhibitor Market conversation — a $839M market you can size, segment and defend in minutes.
Market size · 2033$839Mtotal opportunity
Growth4.2%CAGR to 2033
Addressable buyers1,659+accounts in scope
Typical ROI6.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.8×return on cost, year one
< 3 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Roche Holding AGGlaxoSmithKline plcHetero Drugs LimitedCipla LimitedSun Pharmaceutical Industries LtdMylan N.V.Zhejiang Hisun Pharmaceutical Co. Ltd.Aurobindo Pharma Limited+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Neuraminidase Inhibitor Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Neuraminidase Inhibitor Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Neuraminidase Assay Kit Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportNeural Navigator System Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportNeural Navigator (NeNa) Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportNeural Micro Guidewire Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportNeural Control Interface Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportNeuN Antibody Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportNeulasta (Pegfilgrastim) and Biosimilar Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportNEU3 Antibody Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportNetwork Point-of-Care Glucose Testing Device Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportNetworked Pulse Oximeter Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportNetworked Pill Box Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportNetworked Glucose Meter Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.